Alimera, pSivida dive on FDA second rejection of DMO drug
This article was originally published in Scrip
Executive Summary
Shares of Alimera Sciences plummeted as low as 76.8%, or $5.66, on 11 November after the company revealed that the US FDA for the second time rejected the biotech's experimental diabetic macular oedema (DMO) Iluvien (fluocinolone acetonide intravitreal insert) and called for more clinical testing before the agency considers granting approval – catching the firm and Wall Street off guard.